VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.
about
Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistanceDocetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.Polymorphisms of vascular endothelial growth factor on prognosis in osteosarcoma patients.Interplay between 3'-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans.Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor ActivityMetronomic chemotherapy.A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials.Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.Current achievements and future perspectives of metronomic chemotherapy.Resistance to metronomic chemotherapy and ways to overcome it.Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.Association Between 12 Polymorphisms of VEGF/Hypoxia/Angiogenesis Pathway Genes and Risk of Urogenital Carcinomas: A Meta-Analysis Based on Case-Control Studies.
P2860
Q27023579-98F6C84B-A9F1-462C-B2C1-2700E947F582Q33416977-25CB489C-EB5A-4793-AB2B-BF32552EB072Q34173001-483AA9E1-66B0-452A-B6FD-4CC834E9D7CDQ34176244-1B308308-7C33-4172-8317-55B0D54A951CQ34894525-A0287C15-55C2-4E11-A5C8-09F5AD362CA5Q38203261-F86B911B-E52B-4A1B-9F63-5C8E02915581Q38248269-659B927E-BA29-490D-87EB-E2D046BE1432Q38249998-A0DFCCF6-3083-42ED-A797-A552F42E0336Q38638654-0A7C03E0-9AA9-456B-BB3E-66729E934BC2Q38722809-F9CA6372-EBCC-495E-A954-BE59993C4C3DQ38788234-D4C26515-C37B-4480-B6CE-62B6007C97B8Q40448516-385D034F-76A2-452F-B189-91091974B3CEQ40657628-50E187FF-CF33-4E10-BEFE-280D160D153BQ55475464-19E3093A-E93C-451D-BAC2-54AE04E0D48C
P2860
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
VEGF-A polymorphisms predict p ...... h metronomic cyclophosphamide.
@en
VEGF-A polymorphisms predict p ...... h metronomic cyclophosphamide.
@nl
type
label
VEGF-A polymorphisms predict p ...... h metronomic cyclophosphamide.
@en
VEGF-A polymorphisms predict p ...... h metronomic cyclophosphamide.
@nl
prefLabel
VEGF-A polymorphisms predict p ...... h metronomic cyclophosphamide.
@en
VEGF-A polymorphisms predict p ...... h metronomic cyclophosphamide.
@nl
P2093
P2860
P50
P356
P1476
VEGF-A polymorphisms predict p ...... th metronomic cyclophosphamide
@en
P2093
A Fioravanti
R Marconcini
P2860
P2888
P304
P356
10.1038/BJC.2013.398
P407
P577
2013-07-16T00:00:00Z